BRPI0614790A2 - formas de dosagem sólidas de valsartan e amlodipina, e método de produção das mesmas - Google Patents
formas de dosagem sólidas de valsartan e amlodipina, e método de produção das mesmas Download PDFInfo
- Publication number
- BRPI0614790A2 BRPI0614790A2 BRPI0614790-9A BRPI0614790A BRPI0614790A2 BR PI0614790 A2 BRPI0614790 A2 BR PI0614790A2 BR PI0614790 A BRPI0614790 A BR PI0614790A BR PI0614790 A2 BRPI0614790 A2 BR PI0614790A2
- Authority
- BR
- Brazil
- Prior art keywords
- valsartan
- amlodipine
- solid dosage
- dosage form
- mixed
- Prior art date
Links
- 239000007909 solid dosage form Substances 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 40
- 229940043102 valsartan and amlodipine Drugs 0.000 title abstract description 16
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims abstract description 90
- 229960004699 valsartan Drugs 0.000 claims abstract description 90
- 239000007787 solid Substances 0.000 claims abstract description 48
- 239000002552 dosage form Substances 0.000 claims abstract description 47
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims abstract 16
- 239000000463 material Substances 0.000 claims description 157
- 229960000528 amlodipine Drugs 0.000 claims description 58
- 238000002156 mixing Methods 0.000 claims description 46
- 239000000654 additive Substances 0.000 claims description 30
- 238000005469 granulation Methods 0.000 claims description 29
- 230000003179 granulation Effects 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 22
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 18
- 239000007888 film coating Substances 0.000 claims description 18
- 238000009501 film coating Methods 0.000 claims description 18
- 239000000314 lubricant Substances 0.000 claims description 17
- 238000003801 milling Methods 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000000975 dye Substances 0.000 claims description 7
- 229960004005 amlodipine besylate Drugs 0.000 claims description 6
- -1 glidants Substances 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 3
- 201000009623 Myopathy Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 69
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 62
- 239000010410 layer Substances 0.000 description 57
- 239000003826 tablet Substances 0.000 description 47
- 239000004615 ingredient Substances 0.000 description 35
- 238000009792 diffusion process Methods 0.000 description 30
- 239000002356 single layer Substances 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 16
- 238000005056 compaction Methods 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 150000004104 valsartan derivatives Chemical class 0.000 description 6
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- YQLPCBNEPNLCEP-UHFFFAOYSA-N 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-3-ethyl-5,6-dimethylpiperidine-3,5-dicarboxylic acid;benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCC1(C(O)=O)C(COCCN)NC(C)C(C)(C(O)=O)C1C1=CC=CC=C1Cl YQLPCBNEPNLCEP-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229950004221 besilate Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940030337 valsartan 320 mg Drugs 0.000 description 1
- 230000006815 ventricular dysfunction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70908305P | 2005-08-17 | 2005-08-17 | |
| US60/709,083 | 2005-08-17 | ||
| PCT/US2006/031699 WO2007022113A2 (en) | 2005-08-17 | 2006-08-15 | Solid dosage forms of valsartan and amlodipine and method of making the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0614790A2 true BRPI0614790A2 (pt) | 2011-04-12 |
Family
ID=37758280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0614790-9A BRPI0614790A2 (pt) | 2005-08-17 | 2006-08-15 | formas de dosagem sólidas de valsartan e amlodipina, e método de produção das mesmas |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20080171086A1 (enExample) |
| EP (1) | EP1917002A2 (enExample) |
| JP (2) | JP2009504744A (enExample) |
| KR (3) | KR20120135356A (enExample) |
| CN (1) | CN101237859A (enExample) |
| AR (1) | AR055120A1 (enExample) |
| AU (2) | AU2006279670A1 (enExample) |
| BR (1) | BRPI0614790A2 (enExample) |
| CA (1) | CA2617367A1 (enExample) |
| EC (1) | ECSP088188A (enExample) |
| GT (1) | GT200600371A (enExample) |
| IL (1) | IL189021A0 (enExample) |
| MA (1) | MA29734B1 (enExample) |
| MX (1) | MX2008002267A (enExample) |
| NO (1) | NO20081310L (enExample) |
| NZ (1) | NZ565020A (enExample) |
| PE (1) | PE20070420A1 (enExample) |
| RU (2) | RU2008109913A (enExample) |
| TN (1) | TNSN08071A1 (enExample) |
| TW (1) | TW200740432A (enExample) |
| WO (1) | WO2007022113A2 (enExample) |
| ZA (1) | ZA200800397B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US8951562B2 (en) * | 2006-11-10 | 2015-02-10 | Atacama Labs Oy | Method and apparatus or dry granulation |
| FI20070521A7 (fi) | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
| TR200703568A1 (tr) * | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
| WO2009061713A1 (en) | 2007-11-06 | 2009-05-14 | Novartis Ag | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
| MX2010007281A (es) * | 2007-12-31 | 2010-10-05 | Lupin Ltd | Composiciones farmaceuticas de amlodipina y valsartan. |
| EP2291233B1 (en) | 2008-05-09 | 2019-09-04 | Atacama Labs Oy | Method for dry granulation |
| JO3239B1 (ar) | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| DE102008051783A1 (de) * | 2008-10-17 | 2010-04-22 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Valsartan enthaltende Tablette |
| WO2010104485A2 (en) * | 2009-03-11 | 2010-09-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
| CN101926798B (zh) * | 2009-06-26 | 2013-09-18 | 北京德众万全药物技术开发有限公司 | 一种含有氨氯地平和缬沙坦的分散片 |
| US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
| CN101647797B (zh) * | 2009-09-18 | 2011-06-08 | 海南锦瑞制药股份有限公司 | 一种含有苯磺酸氨氯地平和缬沙坦的药物组合物及其制备方法 |
| CN102091069A (zh) * | 2009-12-11 | 2011-06-15 | 浙江华海药业股份有限公司 | 缬沙坦和氨氯地平的复方制剂及其制备方法 |
| CN101897675B (zh) * | 2010-02-10 | 2012-11-21 | 温士顿医药股份有限公司 | 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物 |
| CN101843615A (zh) * | 2010-06-25 | 2010-09-29 | 包丽昕 | 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法 |
| TR201102067A1 (tr) | 2011-03-03 | 2012-09-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Valsartan ve amlodipin kombinasyonları. |
| CN102283837A (zh) * | 2011-07-29 | 2011-12-21 | 江苏省药物研究所有限公司 | 缬沙坦和氨氯地平复方的固体制剂的制备方法 |
| CN102697778B (zh) * | 2012-06-21 | 2014-04-30 | 上海医药集团股份有限公司 | 缬沙坦氨氯地平复方固体制剂及其制备方法 |
| WO2013191668A1 (en) | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
| WO2014058047A1 (ja) * | 2012-10-12 | 2014-04-17 | 味の素株式会社 | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 |
| CN103006649B (zh) * | 2012-12-27 | 2014-06-25 | 石家庄市华新药业有限责任公司 | 一种复方制剂缬沙坦氨氯地平片（ⅰ）及其制备方法 |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| MX380070B (es) * | 2015-07-08 | 2025-03-11 | Cj Healthcare Corp | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. |
| CN105232551A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/苯磺酸氨氯地平复方制剂及其制备方法 |
| CN106176744A (zh) * | 2016-07-13 | 2016-12-07 | 精华制药集团股份有限公司 | 缬沙坦氨氯地平胶囊在制备治疗脑中风的药物中的应用 |
| ES3035030T3 (en) | 2016-10-07 | 2025-08-28 | Silvergate Pharmaceuticals Inc | Amlodipine formulations |
| EP3522888A4 (en) * | 2016-10-10 | 2020-06-10 | Alembic Pharmaceuticals Limited | STABLE PHARMACEUTICAL COMPOSITION WITH TELMISARTAN AND AMLODIPINE BESYLATE |
| CN109498626A (zh) * | 2017-09-14 | 2019-03-22 | 北京万全德众医药生物技术有限公司 | 一种稳定的复方制剂缬沙坦氨氯地平处方及其制备方法 |
| US10799453B2 (en) | 2018-04-11 | 2020-10-13 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
| CN109260160A (zh) * | 2018-08-30 | 2019-01-25 | 天津仁生医药科技有限公司 | 一种缬沙坦氨氯地平片剂及其制备方法 |
| CN109010338B (zh) * | 2018-09-13 | 2021-09-21 | 合肥合源药业有限公司 | 一种缬沙坦氨氯地平片的制备方法及缬沙坦氨氯地平片 |
| CN109157526A (zh) * | 2018-09-13 | 2019-01-08 | 合肥合源药业有限公司 | 一种缬沙坦氨氯地平复方制剂及其制备工艺 |
| CN109394712B (zh) * | 2018-11-23 | 2019-11-12 | 海南妙音春制药有限公司 | 一种缬沙坦氨氯地平复方片剂及其制备方法 |
| WO2025162195A1 (zh) * | 2024-01-30 | 2025-08-07 | 上海汇伦医药股份有限公司 | 包衣复方片剂 |
| CN120392682A (zh) * | 2024-01-30 | 2025-08-01 | 上海汇伦医药股份有限公司 | 速释组合物 |
| CN119925284B (zh) * | 2025-04-09 | 2025-07-11 | 杭州沐源生物医药科技有限公司 | 一种含有厄贝沙坦和氨氯地平的药物组合物及制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3152978B2 (ja) * | 1991-12-17 | 2001-04-03 | 塩野義製薬株式会社 | 二層錠およびその製造方法 |
| DE19539361A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung |
| DK1096932T3 (da) | 1998-07-10 | 2007-10-15 | Novartis Pharma Ag | Antihypertensiv kombination af valsartan og calciumkanalblokker |
| US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| DK1588706T3 (da) | 1998-12-23 | 2012-01-16 | Novartis Ag | Valsartantablet |
| JP3796562B2 (ja) * | 1999-05-26 | 2006-07-12 | ライオン株式会社 | 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法 |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| AR037565A1 (es) * | 2001-11-21 | 2004-11-17 | Synthon Bv | Formas de sales de amlodipina y procedimientos para prepararlas. |
| ES2445041T3 (es) * | 2002-01-16 | 2014-02-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Método para la preparación de telmisartán amorfo |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| WO2005070463A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| EP1559419A1 (en) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
| AU2006206738A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| WO2007001067A2 (en) * | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
-
2006
- 2006-08-11 GT GT200600371A patent/GT200600371A/es unknown
- 2006-08-15 WO PCT/US2006/031699 patent/WO2007022113A2/en not_active Ceased
- 2006-08-15 AU AU2006279670A patent/AU2006279670A1/en not_active Abandoned
- 2006-08-15 MX MX2008002267A patent/MX2008002267A/es unknown
- 2006-08-15 JP JP2008527038A patent/JP2009504744A/ja active Pending
- 2006-08-15 BR BRPI0614790-9A patent/BRPI0614790A2/pt not_active IP Right Cessation
- 2006-08-15 PE PE2006000992A patent/PE20070420A1/es not_active Application Discontinuation
- 2006-08-15 KR KR1020127030872A patent/KR20120135356A/ko not_active Abandoned
- 2006-08-15 EP EP06813435A patent/EP1917002A2/en not_active Withdrawn
- 2006-08-15 CN CNA2006800289354A patent/CN101237859A/zh active Pending
- 2006-08-15 NZ NZ565020A patent/NZ565020A/en not_active IP Right Cessation
- 2006-08-15 KR KR1020127014789A patent/KR20120078751A/ko not_active Ceased
- 2006-08-15 CA CA002617367A patent/CA2617367A1/en not_active Abandoned
- 2006-08-15 US US11/914,159 patent/US20080171086A1/en not_active Abandoned
- 2006-08-15 AR ARP060103556A patent/AR055120A1/es not_active Application Discontinuation
- 2006-08-15 RU RU2008109913/15A patent/RU2008109913A/ru unknown
- 2006-08-15 KR KR1020087003704A patent/KR20080034159A/ko not_active Withdrawn
- 2006-08-16 TW TW095130129A patent/TW200740432A/zh unknown
-
2008
- 2008-01-14 ZA ZA200800397A patent/ZA200800397B/xx unknown
- 2008-01-24 IL IL189021A patent/IL189021A0/en unknown
- 2008-02-08 MA MA30630A patent/MA29734B1/fr unknown
- 2008-02-15 EC EC2008008188A patent/ECSP088188A/es unknown
- 2008-02-15 TN TNP2008000071A patent/TNSN08071A1/en unknown
- 2008-03-12 NO NO20081310A patent/NO20081310L/no not_active Application Discontinuation
-
2010
- 2010-08-09 US US12/852,542 patent/US20100303906A1/en not_active Abandoned
- 2010-10-08 AU AU2010227062A patent/AU2010227062A1/en not_active Abandoned
-
2012
- 2012-02-23 US US13/403,638 patent/US20120177733A1/en not_active Abandoned
- 2012-07-24 RU RU2012131668/15A patent/RU2012131668A/ru not_active Application Discontinuation
-
2013
- 2013-01-17 JP JP2013006668A patent/JP2013091660A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101237859A (zh) | 2008-08-06 |
| GT200600371A (es) | 2007-03-21 |
| US20080171086A1 (en) | 2008-07-17 |
| KR20120078751A (ko) | 2012-07-10 |
| AR055120A1 (es) | 2007-08-08 |
| TNSN08071A1 (en) | 2009-07-14 |
| PE20070420A1 (es) | 2007-05-21 |
| AU2006279670A1 (en) | 2007-02-22 |
| EP1917002A2 (en) | 2008-05-07 |
| ECSP088188A (es) | 2008-03-26 |
| KR20120135356A (ko) | 2012-12-12 |
| JP2009504744A (ja) | 2009-02-05 |
| RU2008109913A (ru) | 2009-09-27 |
| NO20081310L (no) | 2008-05-16 |
| ZA200800397B (en) | 2009-03-25 |
| KR20080034159A (ko) | 2008-04-18 |
| IL189021A0 (en) | 2008-08-07 |
| WO2007022113A2 (en) | 2007-02-22 |
| MX2008002267A (es) | 2008-03-27 |
| JP2013091660A (ja) | 2013-05-16 |
| US20120177733A1 (en) | 2012-07-12 |
| CA2617367A1 (en) | 2007-02-22 |
| US20100303906A1 (en) | 2010-12-02 |
| WO2007022113A3 (en) | 2007-05-10 |
| TW200740432A (en) | 2007-11-01 |
| MA29734B1 (fr) | 2008-09-01 |
| NZ565020A (en) | 2011-07-29 |
| AU2010227062A1 (en) | 2010-11-04 |
| RU2012131668A (ru) | 2014-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0614790A2 (pt) | formas de dosagem sólidas de valsartan e amlodipina, e método de produção das mesmas | |
| DK3017811T3 (en) | APIXABAN FORMULATIONS | |
| CN101478956B (zh) | 缬沙坦、氨氯地平和氢氯噻嗪的固体剂型及制备该固体剂型的方法 | |
| JP2009542709A5 (enExample) | ||
| US8545884B2 (en) | Solid pharmaceutical formulations comprising BIBW 2992 | |
| ES2689685T3 (es) | Una composición farmacéutica estable que contiene amlodipina y valsartán | |
| EA019614B1 (ru) | Усовершенствованная фармацевтическая композиция, содержащая антагонист дигидропиридинкальциевого канала, и способ ее получения | |
| JP5719385B2 (ja) | ラミプリル及びベシル酸アムロジピンの固形医薬製剤及びその製造 | |
| US10668073B2 (en) | Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof | |
| JP2012503020A5 (enExample) | ||
| AU2013100625B4 (en) | Solid dosage forms of valsartan and amlodipine and method of making the same | |
| AU2013200050A1 (en) | Solid dosage forms of valsartan and amlodipine and method of making the same | |
| WO2009063484A2 (en) | Stable pharmaceutical composition of lamotrigine | |
| DK3173075T3 (en) | PHARMACEUTICAL COMBINATION PREPARATION OF ACE INHIBITOR AND LOOPDIURETIC | |
| BR112019006506B1 (pt) | Comprimidos compreendendo 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il) piridin-3-il)metóxi) benzaldeído e uso dos mesmos | |
| HK1133818B (en) | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same | |
| OA19661A (en) | Tablets comprising 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-YL) Pyridin-3-YL) Methoxy) Benzaldehyde. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2320 DE 23-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |